A healthy dose of experience. Pharmaceutical
Companies choose us to be their IP counsel because having previously worked and performed research at pharmaceutical giants, innovative start-ups, and renowned universities, we have first-hand knowledge of how important patents, trademarks, and trade secrets are to our clients’ businesses.
The Rx for legal complexities.
We understand the complex interaction between patents and regulatory exclusivity, including patent term extensions, non-patent exclusivities, Orange Book listing requirements, Hatch-Waxman issues, and ANDA litigation. Working closely with your team to navigate rules, processes, and procedures, we leverage our IP, regulatory, and technical experience to devise patent and regulatory strategy that helps you achieve your goals.
![220811-StudioNouveau0024](https://wolfgreenfield.com/hs-fs/hubfs/220811-StudioNouveau0024.jpg?width=600&height=400&name=220811-StudioNouveau0024.jpg)
Our clients include global and emerging pharmaceutical companies like Takeda, Vertex Pharmaceuticals, and Viamet Pharmaceuticals, as well as prestigious academic and research institutions like Harvard University, MIT, The Broad Institute, Dana-Farber Cancer Institute, and Memorial Sloan Kettering. They appreciate our depth of experience as well as our attention to client service.
Members of our group have extensive experience in the pharma industry, having worked at companies like Johnson & Johnson, Novartis, and GlaxoSmithKline, and having worked as in-house legal counsel at companies including Cubist Pharmaceuticals and Amgen. We have a first-hand understanding of the challenges in-house counsel face.
Working closely with our clients, we customize IP infrastructures that coordinate with and complement existing in-house protocols and systems. We create strategic plans for portfolios, and adjust as IP and business needs dictate. We are forward-looking and proactive about filing strategies, always keeping in mind potential collaboration and licensing opportunities as well as future R&D efforts.
We represent clients in areas such as: Drug Delivery, Drug Discovery, Formulation Development, Screening Technologies, Polymers, Polymorphs, and Synthetic Methodology.
Awards & Recognition
![Top-Lawyers-Logo-2022_rgb_black](https://wolfgreenfield.com/hs-fs/hubfs/Top-Lawyers-Logo-2022_rgb_black.png?width=100&height=100&name=Top-Lawyers-Logo-2022_rgb_black.png)
Boston Magazine
Our team’s academic backgrounds include:
- Biochemistry
- Biology
- Catalysis
- Chemistry
- Chemical Biology
- Chemical Engineering
- Formulation Chemistry
- Immunology
- Medicinal Chemistry
- Molecular Biology
- Organic Chemistry
- Organometallic Chemistry
- Polymer Chemistry
- Process Chemistry
- Toxicology
![Bubbles or cells in liquid](https://wolfgreenfield.com/hs-fs/hubfs/WG_Pharm-2.jpg?width=1000&height=1000&name=WG_Pharm-2.jpg)
Why clients feel confident in our work.
Wolf Greenfield has been a trusted partner for years. The team is highly collaborative, proactive, and has a proven track-record of developing creative strategies to protect our complete IP portfolio.
Wolf Greenfield's greatest service strengths are its excellent knowledge of science, patent law/prosecution, and ability to clearly and effectively communicate with me and our scientists and licensees.
Wolf Greenfield hires well, does great work, and is fantastic to work with.
Wolf Greenfield has always met our needs and given us confidence in their advice.
The attorneys with whom we work are incredibly responsive.
They check all the boxes in terms of technical ability, day-to-day management and everything I could want in a patent prosecutor. They deliver all of that.
Pharmaceutical Experience
News & Insights
View more insightsUSPTO Proposed Terminal Disclaimer Can Terminate Patents
The USPTO on May 10, 2024, issued a notice of proposed rulemaking (NPRM) raising the requirements for accepting a Terminal Disclaimer (TD) to obviate obviousness-type double patenting (ODP). Specifica...
![blue background with caution sign](https://wolfgreenfield.com/hs-fs/hubfs/Alert.png?width=450&height=337&name=Alert.png)
Proposed March-In Guidance Signals Funding Agencies to Actively Evaluate Government Rights Under the Bayh-Dole Act
An article authored by Rob Sahr and Curtis Powell titled “Proposed March-In Guidance Signals Funding Agencies to Actively Evaluate Government Rights Under the Bayh-Dole Act” was published in Volume 16...
![bald eagle flying](https://wolfgreenfield.com/hs-fs/hubfs/Article%20&%20News%20Images%20for%20Website%20%28100%29.png?%20News%20Images%20for%20Website%20%28100%29.png%20450w%20}}&%20News%20Images%20for%20Website%20%28100%29.png&width=450&height=337&name=Article%20&%20News%20Images%20for%20Website%20%28100%29.png?%20News%20Images%20for%20Website%20%28100%29.png%20450w%20}}&%20News%20Images%20for%20Website%20%28100%29.png)
Jonathan Roses Mentioned by Managing IP on USPTO’s Enablement Guidance
Jonathan Roses was mentioned by Managing Intellectual Property in an article titled “Raise Your Wands: Counsel Welcome USPTO’s Enablement Guidance.” In this article, counsel weigh in on the guidance p...
![larger than life shot of pillars on a courthouse](https://wolfgreenfield.com/hs-fs/hubfs/Front%20of%20an%20old%20greek%20or%20roman%20style%20law%20building.jpeg?width=450&height=337&name=Front%20of%20an%20old%20greek%20or%20roman%20style%20law%20building.jpeg)
Events
Past Events
LSPN North America 2024
One Nucleus: Boston Bootcamp 2024
UF Innovate Insights Seminar: Intersection of Patent and Regulatory Strategies in Drug Development
Contact
![A headshot of C. Hunter Baker](https://wolfgreenfield.com/hs-fs/hubfs/professionals/headshots/baker-hunter.jpg?width=150&height=150&name=baker-hunter.jpg)